Ocular Therapeutix Inc
Ocular Therapeutix Inc logo
OCUL

Ocular Therapeutix Inc (OCUL)

$5.480.37%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$5.38
Day's Range
$5.6267
$2.91
52-Week Range
$12.5
1 month return27.44%
3 month return63.1%
1 year return45.42%
5 year return17.1%

Company Information

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
OrganizationOcular Therapeutix Inc
Employees181
CEOAntony Mattessich
IndustryHealth Technology

Analyst Recommendation

based on 12 analysts ratings

Buy
83%
Buy
16%
Hold
0%
Sell

Based on 12 Wall street analysts offering stock ratings for Ocular Therapeutix Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 228.47%

Current

$5.48

Target

$18.0

Recommendation Trend

Based on 12 analyst

Current1M Ago3M Ago
Buy
10
11
11
Hold
2
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
303.9M
Book Value
1.15
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-0.98
PEG Ratio
0.0
Wall Street Target Price
20.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
6.98
Price/Book (mrq)
3.19
Enterprise Value
175.7M
Enterprise Value/Revenue
4.04
Enterprise Value/Ebitda
69.22

Technicals

Beta
1.69
50 Day MA
4.93
200 Day MA
7.7

Institutional Holdings

Opaleye Management Inc

7.78%

SUMMER ROAD LLC

7.74%

BlackRock Inc

6.67%

Vanguard Group Inc

5.47%

Deltec Asset Management LLC

2.71%

State Street Corporation

2.22%

Discover more

Frequently Asked Questions

What is Ocular Therapeutix Inc share price today?

Can Indians buy Ocular Therapeutix Inc shares?

How can I buy Ocular Therapeutix Inc shares from India?

Can Fractional shares of Ocular Therapeutix Inc be purchased?

What are the documents required to start investing in Ocular Therapeutix Inc stocks?

What are today’s High and Low prices of Ocular Therapeutix Inc?

What are today’s traded volumes of Ocular Therapeutix Inc?

What is today’s market capitalisation of Ocular Therapeutix Inc?

What is the 52 Week High and Low Range of Ocular Therapeutix Inc?

How much percentage Ocular Therapeutix Inc is down from its 52 Week High?

How much percentage Ocular Therapeutix Inc is up from its 52 Week low?

What are the historical returns of Ocular Therapeutix Inc?

Who is the Chief Executive Officer (CEO) of Ocular Therapeutix Inc?